个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhou Huixing[1] ; Wang Yafei[2] ; Chen Jiao[3] ; He Aili[4] ; Jin Jie[5] ; Lu Quanyi[6] ; Zhao Ying[7] ; Li Junjun[8] ; Hou Ming[9] ; Su Liping[10] ; Lai Xun[11] ; Wang Wei[12] ; Liu Lihong[13] ; Ma Yanping[14] ; Gao Da[15] ; Lai Wenhong[16] ; Zhou Xin[17] ; Jing Hongmei[18] ; Zhang Jinqiao[19] ; Yang Wei[20] ; Ran Xuehong[21] ; Lin Congmeng[22] ; Hao Jianping[23] ; Xiao Taiwu[24] ; Huang Zhenqian[25] ; Zhu Zhigang[26] ; Wang Qing[27] ; Fang Baijun[28] ; Wang Binghua[29] ; Song Yanping[30] ; Cai Zhen[31] ; Liu Bo[32] ; Zhu Yanan[32] ; Yang Xinai[32] ; Kang Xiaoyan[32] ; Li Juan[33] ; Chen Wenming[1] ;
机构： [1]Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, #8, the South Road of Workers Stadium of Chaoyang District, Beijing, 100020, China. [2]Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. [3]Department of Hematology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Chengdu, China. [4]Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. [5]Department of Hematology, The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. [6]Department of Hematology, Zhongshan Hospital Affiliated to Xiamen University, Xiamen, China. [7]Department of Hematology, The First People's Hospital of Foshan, Guangzhou, China. [8]Department of Hematology, The First Affiliated Hospital of University of South China, Hengyang, China. [9]Department of Hematology, Qilu Hospital of Shandong University, Jinan, China. [10]Department of Hematology, Shanxi Provincial Cancer Hospital, Taiyuan, China. [11]Department of Hematology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Center, Kunming, China. [12]Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China. [13]Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [14]Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China. [15]Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China. [16]Department of Hematology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China. [17]Department of Hematology, Wuxi People's Hospital, Wuxi, China. [18]Department of Hematology, Peking University Third Hospital, Beijing, China. [19]Department of Hematology, The Third Hospital of Hebei Medical University, Shijiazhuang, China. [20]Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China. [21]Department of Hematology, Weifang People's Hospital, Weifang, China. [22]Department of Hematology, Zhangzhou Municicap Hospital of Fujian Province, Zhangzhou, China. [23]Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumchi, China. [24]Department of Hematology, Liaocheng People's Hospital, Liaocheng, China. [25]Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. [26]Department of Geriatric Hematologic Oncology, Guangzhou First People's Hospital, Guangzhou, China. [27]Department of Hematopathology, Guizhou Provincial People's Hospital, Guiyang, China. [28]Department of Hematology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhenghzou University, Zhengzhou, China. [29]Department of Hemolymph, Weihai Central Hospital, Weihai, China. [30]Department of Hematology, Xi'an Central Hospital, Xi'an, China. [31]Bone Marrow Transplantation Center, the First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. [32]Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China. [33]Department of Hematology, First Affiliated Hospital of Sun Yat-Sen University, #58, The 2nd Zhongshan Road, Yuexiu District, Guangzhou, 510062, China.
出处：
DOI： 10.1007/s00277-023-05558-y
ISSN：

关键词： Pomalidomide  Generic drug  Relapse and/or refractory multiple myeloma (RRMM)  Dexamethasone

摘要：
This multicenter, open-label, single-arm trial (ClinicalTrials.gov, NCT05236621) was conducted to confirm the efficacy and safety of generic pomalidomide plus dexamethasone in Chinese patients with relapsed or refractory multiple myeloma (RRMM). Total 79 eligible RRMM patients were planned to be included. Patients were treated with generic pomalidomide (4 mg daily on days 1-21, orally) and low-dose dexamethasone (40 mg/day on days 1, 8, 15, and 22, orally; 20 mg for patients aged > 75 years) in 28-day cycles until disease progression with a maximum treatment duration of 2 years. The primary endpoint is the overall response rate (ORR) assessed by the independent review committee per the 2016 International Myeloma Working Group guidelines. A total of 85 eligible patients were included in this study from 32 centers in China, with a median age of 62.0 (range, 39-76) years, a median prior line of therapy of 4 (range, 1-16), and 41.2% patients with high-risk cytogenetics. The ORR was 38.8% (95% confidence interval (CI), 28.44-50.01). The disease control rate was 67.1% (95% CI, 56.02-76.87), meanwhile, the median progression-free survival was 5.55 months (95% CI, 3.68-7.52). Among the treatment-related adverse events (TRAEs), infective pneumonia (17.6%) was the most frequent non-hematologic adverse event, while a decrease in neutrophil count (52.9%) was the most common grade ≥ 3 TRAE. The study results indicated that the generic pomalidomide demonstrated consistent efficacy and a safety profile similar to the branded pomalidomide when combined with low-dose dexamethasone in Chinese RRMM patients.Registration number ClinicalTrials.gov NCT05236621, retrospectively registered on February 11, 2022.© 2023. The Author(s).

语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 3 区 医学
小类 | 3 区 血液学
最新[2023]版：
大类 | 3 区 医学
小类 | 3 区 血液学
JCR分区：
出版当年[2023]版：
Q2 HEMATOLOGY
最新[2023]版：
Q2 HEMATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, #8, the South Road of Workers Stadium of Chaoyang District, Beijing, 100020, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Zhou Huixing,Wang Yafei,Chen Jiao,et al.Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial[J].ANNALS OF HEMATOLOGY.2024,103(3):855-868.doi:10.1007/s00277-023-05558-y.
APA：
Zhou Huixing,Wang Yafei,Chen Jiao,He Aili,Jin Jie...&Chen Wenming.(2024).Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.ANNALS OF HEMATOLOGY,103,(3)
MLA：
Zhou Huixing,et al."Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial".ANNALS OF HEMATOLOGY 103..3(2024):855-868

相关文献

[1]The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis [2]Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial [3]Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS [4]Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study [5]地塞米松软膏对预防诺维苯所致静脉炎的效果观察 [6]Dexamethasone Stimulates Hepatitis B Virus (HBV) Replication Through Autophagy [7]Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study. [8]Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study. [9]Efficacy of gemcitabine combined with oxaliplatin, L-asparaginase and dexamethasone in patients with newly-diagnosed extranodal NK/T-cell lymphoma [10]Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone.

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号